Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease
We examined the "therapeutic time window" eligibility for disease-modifying therapy.Longitudinal data from National Alzheimer's Coordinating Center (NACC) and Alzheimer's Disease Neuroimaging Initiative (ADNI) were used to quantify eligibility duration.Higher Clinical Dementia Rating-Global Score (CDR-GS) or lower Mini-Mental State Examination (MMSE) at baseline were associated with shorter window length.Our results will help optimize the management of the wait time for disease-modifying therapies (DMT) treatment.
Authors
- Kenichiro Sato (ORCID: https://orcid.org/0000-0003-4351-9526)
- Yoshiki Niimi (ORCID: https://orcid.org/0000-0002-2556-8167)
- Takeshi Iwatsubo (ORCID: https://orcid.org/0000-0003-1160-8129)
- Ryoko Ihara (ORCID: https://orcid.org/0000-0001-8770-3283)
- Atsushi Iwata (ORCID: https://orcid.org/0000-0001-7308-5314)
- Kazushi Suzuki (ORCID: https://orcid.org/0000-0001-7841-7533)
- Tatsushi Toda
- Shigeru Nakashima
Institutions
- University of Tokyo Hospital (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
- National Defense Medical College (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70102
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science